Grufity logo
Grufity logo
BIVI

BIVI - BioVie Inc. Stock Price, Fair Value and News

$1.79+0.13 (+7.83%)
Market Closed as of 16 Jun 2026, 04:00 pm ET

45/100

BIVI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

45/100

BIVI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BIVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIVI Price Action

Last 7 days

-0.6%

Last 30 days

26.7%

Last 90 days

18.6%

Trailing 12 Months

-85.4%

BIVI RSI Chart

BIVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIVI Valuation

Market Cap

13.5M

Price/Earnings (Trailing)

-0.68

Price/Sales (Trailing)

18.85

Price/Free Cashflow

-0.66

BIVI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BIVI Fundamentals

BIVI Revenue

Revenue (TTM)

716.4K

BIVI Earnings

Earnings (TTM)

-19.9M

Earnings Growth (Yr)

-89.01%

Earnings Growth (Qtr)

13.17%

BIVI Profitability

Return on Equity

-127.61%

Return on Assets

-113.71%

Free Cashflow Yield

-151.93%

BIVI Investor Care

Buy Backs (1Y)

59.27%

Diluted EPS (TTM)

-8.18

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026716.4K---
2025757.4K-873.1K848.4K
2024--359.9K601.4K
202240.2K44.1K78.0K149.6K
2021-22.0K28.8K35.6K
2020----
2019----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About BioVie Inc.

BIVI
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
 CEO
 WEBSITEhttps://bioviepharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES18

BioVie Inc. Frequently Asked Questions

BIVI is the stock ticker symbol of BioVie Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Jun 15 2026, market cap of BioVie Inc. is 12.52 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Jun 15 2026, BIVI's PE ratio (Price to Earnings) is -0.63 and Price to Sales (PS) ratio is 17.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIVI PE ratio will change depending on the future growth rate expectations of investors.